Mutual of America Capital Management LLC Sells 868 Shares of Regeneron Pharmaceuticals, Inc. $REGN

Mutual of America Capital Management LLC lowered its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 7.3% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 11,024 shares of the biopharmaceutical company’s stock after selling 868 shares during the period. Mutual of America Capital Management LLC’s holdings in Regeneron Pharmaceuticals were worth $6,198,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the business. State Street Corp lifted its holdings in shares of Regeneron Pharmaceuticals by 0.9% during the second quarter. State Street Corp now owns 4,832,002 shares of the biopharmaceutical company’s stock valued at $2,536,801,000 after purchasing an additional 42,343 shares in the last quarter. Dodge & Cox increased its holdings in Regeneron Pharmaceuticals by 64.6% in the 2nd quarter. Dodge & Cox now owns 3,826,283 shares of the biopharmaceutical company’s stock worth $2,008,799,000 after buying an additional 1,502,198 shares in the last quarter. Franklin Resources Inc. lifted its stake in Regeneron Pharmaceuticals by 1.6% during the 2nd quarter. Franklin Resources Inc. now owns 2,313,496 shares of the biopharmaceutical company’s stock valued at $1,214,585,000 after acquiring an additional 36,821 shares during the period. Loomis Sayles & Co. L P lifted its position in Regeneron Pharmaceuticals by 18.6% during the second quarter. Loomis Sayles & Co. L P now owns 1,941,070 shares of the biopharmaceutical company’s stock valued at $1,019,062,000 after purchasing an additional 305,089 shares during the period. Finally, Norges Bank purchased a new position in shares of Regeneron Pharmaceuticals in the 2nd quarter worth $628,151,000. 83.31% of the stock is owned by institutional investors.

Insiders Place Their Bets

In related news, VP Jason Pitofsky sold 431 shares of the company’s stock in a transaction that occurred on Friday, November 7th. The stock was sold at an average price of $651.43, for a total value of $280,766.33. Following the sale, the vice president owned 4,233 shares in the company, valued at $2,757,503.19. This represents a 9.24% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Bonnie L. Bassler sold 1,500 shares of the stock in a transaction on Wednesday, January 7th. The stock was sold at an average price of $800.00, for a total transaction of $1,200,000.00. Following the completion of the sale, the director owned 1,703 shares in the company, valued at $1,362,400. The trade was a 46.83% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Company insiders own 7.02% of the company’s stock.

Regeneron Pharmaceuticals Price Performance

Shares of REGN stock opened at $751.13 on Thursday. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.33 and a current ratio of 4.06. The stock has a 50 day moving average price of $758.43 and a 200 day moving average price of $647.96. Regeneron Pharmaceuticals, Inc. has a 52-week low of $476.49 and a 52-week high of $821.11. The firm has a market capitalization of $78.94 billion, a P/E ratio of 17.99, a P/E/G ratio of 2.01 and a beta of 0.39.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its earnings results on Tuesday, October 28th. The biopharmaceutical company reported $11.83 EPS for the quarter, topping analysts’ consensus estimates of $9.73 by $2.10. The business had revenue of $3.75 billion for the quarter, compared to analyst estimates of $3.57 billion. Regeneron Pharmaceuticals had a net margin of 32.13% and a return on equity of 13.76%. The company’s quarterly revenue was up .9% compared to the same quarter last year. During the same period last year, the company posted $12.46 earnings per share. As a group, sell-side analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on REGN. UBS Group boosted their price objective on shares of Regeneron Pharmaceuticals from $595.00 to $660.00 and gave the company a “neutral” rating in a research report on Friday, November 7th. Zacks Research upgraded shares of Regeneron Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Thursday, January 8th. Weiss Ratings reissued a “hold (c)” rating on shares of Regeneron Pharmaceuticals in a report on Monday, December 29th. Guggenheim boosted their price objective on Regeneron Pharmaceuticals from $815.00 to $865.00 and gave the company a “buy” rating in a research report on Wednesday, October 29th. Finally, Morgan Stanley increased their target price on Regeneron Pharmaceuticals from $767.00 to $768.00 and gave the stock an “equal weight” rating in a research report on Friday, December 12th. Three research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and eight have issued a Hold rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $784.77.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.